2025
Eligibility Criteria in Advanced Urothelial Cancer Clinical Trials: An Assessment of Modernization and Inclusion
Mercier B, Govindarajan A, Castro D, Li X, Philip E, Feng M, Prajapati S, Chan E, Lee K, Sehgal I, Patel J, O'Dell A, Chehrazi‐Raffle A, Ebrahimi H, Rock A, Zengin Z, Meza L, Dizman N, Hsu J, Liu S, Dorff T, Pal S, Tripathi A. Eligibility Criteria in Advanced Urothelial Cancer Clinical Trials: An Assessment of Modernization and Inclusion. Cancer Medicine 2025, 14: e70696. PMID: 40145383, PMCID: PMC11947756, DOI: 10.1002/cam4.70696.Peer-Reviewed Original ResearchConceptsHepatitis B/C infectionHIV infectionClinical trialsConcurrent malignancyBrain metastasesVariant histologyEligibility criteriaPresence of brain metastasesAmerican Society of Clinical OncologyMetastatic urothelial cancerFisher's exact testType of therapyContemporary clinical trialsFriends of Cancer ResearchInclusion of patientsUrothelial cancerExact testClinical OncologyTherapy efficacyCancer clinical trialsCancer trialsHIVPatientsExclusion criteriaInfection
2023
Systemic Anticancer Therapy and Thromboembolic Outcomes in Hospitalized Patients With Cancer and COVID-19
Gulati S, Hsu C, Shah S, Shah P, Zon R, Alsamarai S, Awosika J, El-Bakouny Z, Bashir B, Beeghly A, Berg S, de-la-Rosa-Martinez D, Doroshow D, Egan P, Fein J, Flora D, Friese C, Fromowitz A, Griffiths E, Hwang C, Jani C, Joshi M, Khan H, Klein E, Heater N, Koshkin V, Kwon D, Labaki C, Latif T, McKay R, Nagaraj G, Nakasone E, Nonato T, Polimera H, Puc M, Razavi P, Ruiz-Garcia E, Saliby R, Shastri A, Singh S, Tagalakis V, Vilar-Compte D, Weissmann L, Wilkins C, Wise-Draper T, Wotman M, Yoon J, Mishra S, Grivas P, Shyr Y, Warner J, Connors J, Shah D, Rosovsky R, Gandhi R, Gartrell B, Goel S, Halmos B, Makower D, O' Sullivan D, Ohri N, Sica R, Verma A, Butt O, Fiala M, Henderson J, Monahan R, Stockerl-Goldstein K, Zhou A, Bitran J, Hallmeyer S, Mundt D, Pandravada S, Papaioannou P, Patel M, Streckfuss M, Tadesse E, Thompson M, Lammers P, Loree J, Yu I, Bindal P, Lam B, Peters M, Piper-Vallillo A, Arvanitis P, Egan P, Farmakiotis D, Olszewski A, Vieira K, Angevine A, Bar M, Del Prete S, Fiebach M, Gulati A, Hatton E, Houston K, Rose S, Steve Lo K, Stratton J, Weinstein P, Garcia J, Routy B, Hoyo-Ulloa I, Gupta S, Nizam A, Pennell N, Sharifi N, Hoppenot C, Li A, Bitterman D, Choueiri T, Connors J, Demetri G, El Zarif T, Florez N, Freeman D, Giordano A, Morgans A, Nohria A, Tolaney S, Van Allen E, Xu W, Halabi S, Zhang T, Dzimitrowicz H, Leighton J, Graber J, Hawley J, Loggers E, Lyman G, Lynch R, Portuguese A, Schweizer M, Su C, Tachiki L, Vinayak S, Wagner M, Yeh A, Dansoa Y, Gatson N, Makary M, Manikowski J, Vadakara J, Yossef K, Beckerman J, Goyal S, Messing I, Provenzano D, Rao Y, Rosenstein L, Steffes D, Clement J, Cosin J, Daher A, Dailey M, Elias R, Eton O, Hosmer W, Hsu E, Jayaraj A, Mather J, Menendez A, Nadkarni R, Serrano O, Yu P, Gadgeel S, Tejwani S, Accordino M, Bhutani D, Bodin B, Hershman D, Ingham M, Khan S, Masson C, Schwartz G, Alexander M, Matar S, Reuben D, Bernicker E, Deeken J, Jeffords K, Shafer D, Cárdenas-Delgado A, Cuervo Campos R, De-la-Rosa-Martinez D, Ramirez A, Valdez-Reyes N, Gill D, Lewis M, Low C, Rhodes T, Jones M, Mansoor A, Mashru S, Werner M, Cohen A, Hayes-Lattin B, McWeeney S, Nemecek E, Williamson S, Lewis G, Smith S, Akhtari M, Castillo D, Cortez K, Park K, Reeves M, Berg S, O'Connor T, Altman J, Gurley M, Mulcahy M, Wehbe F, Durbin E, Kulkarni A, Nelson H, Ramesh V, Sachs Z, Wilson G, Bardia A, Boland G, Gainor J, Peppercorn J, Reynolds K, Zubiri L, Campian J, Smith K, Bekaii-Saab T, Desai A, Halfdanarson T, Joyner M, Riaz I, Senefeld J, Williams C, Bonnen M, Mahadevan D, Ramirez A, Salazar M, Wang C, Mesa R, Bouganim N, Elkrief A, Moria F, Panasci J, Papenburg J, Vinh D, Nanchal R, Singh H, Bahadur N, Bao T, Nambiar P, O’Cearbhaill R, Papadopoulos E, Philip J, Riely G, Robson M, Rosenberg J, Schoenfeld A, Tamimi R, Cerrone K, Dill J, Faller B, Ajmera A, Brouha S, Choi S, Hsiao A, Reid E, Bhatt P, Mariano M, Thomson C, Glace M, Knoble J, Rink C, Zacks R, Blau S, Brown C, Namburi S, Pomerantz L, Rovito M, Advani P, Cronin T, Fleissner B, Goel S, Gopalakrishnan D, Hernandez-Ilizaliturri F, Jain P, Kariapper A, Levine E, Moffitt M, O'Connor T, Puzanov I, Smith L, Wicher C, Zsiros E, Jabbour S, Misdary C, Shah M, Batist G, Cook E, Esfahani K, Ferrario C, Lau S, Ma K, Miller W, Rudski L, Santos Dutra M, Wilchesky M, Mahmood S, McNair C, Mico V, Rivera A, Dixon B, Heilman H, Logan B, Mandapakala C, Cabebe E, Glover M, Jha A, Khaki A, Nagpal S, Schapira L, Shah S, Wu J, Subbiah S, Whaley D, Lopes G, de Cardenas K, Russell K, Stith B, Taylor S, Klamerus J, Revankar S, Addison D, Chen J, Gatti-Mays M, Jhawar S, Palmer J, Pillainayagam C, Stover D, Wall S, Williams N, Abbasi S, Annis S, Greenland S, Jones R, Kasi A, Rock C, Wulff-Burchfield E, Smits M, Weiss M, Chism D, Owenby S, Ang C, Galsky M, Metzger M, Berenberg J, Uyehara C, Fazio A, Huber K, Lashley L, Sueyoshi M, Patel K, Riess J, Borno H, Small E, Zhang S, Andermann T, Jensen C, Rubinstein S, Wood W, Ahmad S, Grover P, Jandarov R, Kharofa J, Li N, Marcum M, Sohal D, Zamulko O, Abidi M, Balmaceda N, Bowles D, Geiger C, Markham M, Russ A, Saker H, Acoba J, Choi H, Rho Y, Feldman L, Gantt G, Hoskins K, Khan M, Liu L, Nguyen R, Pasquinelli M, Schwartz C, Venepalli N, Vikas P, Zakharia Y, Boldt A, Fecher L, Su C, Bijjula R, Mavromatis B, Seletyn M, Wood B, Zaman Q, Kaklamani V, Brown A, Charles L, Cheng A, Crispens M, Croessmann S, Davis E, Ding T, Duda S, Enriquez K, French B, Gillaspie E, Hausrath D, Hennessy C, Johnson D, Lewis J, Li X, Prescott L, Reid S, Saif S, Shyr Y, Slosky D, Solorzano C, Sun T, Wang L, Yang Y, Aboulafia D, Carducci T, Goldsmith K, Van Loon S, Topaloglu U, Moore J, Cabalona W, Shisler E, Barrow McCollough B, Peddi P, Rosen L, Bilen M, Castellano C, Ravindranathan D, Hafez N, Herbst R, LoRusso P, Lustberg M, Masters T, Stratton C, Painter C, Peters S. Systemic Anticancer Therapy and Thromboembolic Outcomes in Hospitalized Patients With Cancer and COVID-19. JAMA Oncology 2023, 9: 1390-1400. PMID: 37589970, PMCID: PMC10436185, DOI: 10.1001/jamaoncol.2023.2934.Peer-Reviewed Original ResearchConceptsThromboembolic eventsVenous thromboembolismArterial thromboembolismRelative riskTreatment of interestCohort studyMAIN OUTCOMECOVID-19Laboratory-confirmed SARS-CoV-2 infectionHigher intensive care unit admissionMultivariable log-binomial regression analysisRegistry-based retrospective cohort studyHistory of VTEIncidence of VTEIntensive care unit admissionLog-binomial regression analysisSARS-CoV-2 infectionCare unit admissionPoor performance statusRetrospective cohort studySystemic anticancer therapyAnticancer therapyType of therapyCOVID-19 diagnosisActive cancerOsteonecrosis in Gaucher disease in the era of multiple therapies: Biomarker set for risk stratification from a tertiary referral center
Basiri M, Ghaffari M, Ruan J, Murugesan V, Kleytman N, Belinsky G, Akhavan A, Lischuk A, Guo L, Klinger K, Mistry P. Osteonecrosis in Gaucher disease in the era of multiple therapies: Biomarker set for risk stratification from a tertiary referral center. ELife 2023, 12: e87537. PMID: 37249220, PMCID: PMC10317498, DOI: 10.7554/elife.87537.Peer-Reviewed Original ResearchConceptsEnzyme replacement therapySubstrate reduction therapyAvascular osteonecrosisTertiary referral centerGaucher diseaseReferral centerTreatment initiationGD patientsImiglucerase enzyme replacement therapyResidual disease activityAnti-drug antibodiesYears of treatmentType of therapyRare inborn errorMixed-effects logistic modelGD1 patientsSpleen statusDisease activityClinical outcomesRisk stratificationReplacement therapyIndependent correlatesMultiple therapiesReduction therapyHigh risk
2022
Predictive factors and outcomes for ibrutinib in relapsed/refractory marginal zone lymphoma: a multicenter cohort study
Epperla N, Zhao Q, Chowdhury SM, Shea L, Moyo TK, Reddy N, Sheets J, Weiner DM, Geethakumari PR, Kandarpa M, Bruno XJ, Thomas C, Churnetski MC, Hsu A, Zurbriggen L, Tan C, Lindsey K, Maakaron J, Caimi PF, Torka P, Bello C, Ayyappan S, Karmali R, Kim SH, Kress A, Kothari S, Sawalha Y, Christian B, David KA, Greenwell IB, Janakiram M, Kenkre VP, Olszewski AJ, Cohen JB, Palmisiano N, Umyarova E, Wilcox RA, Awan FT, Alderuccio JP, Barta SK, Grover NS, Ghosh N, Bartlett NL, Herrera AF, Shouse G. Predictive factors and outcomes for ibrutinib in relapsed/refractory marginal zone lymphoma: a multicenter cohort study. Journal Of Hematology & Oncology 2022, 15: 96. PMID: 35842643, PMCID: PMC9287914, DOI: 10.1186/s13045-022-01316-1.Peer-Reviewed Original ResearchConceptsMarginal zone lymphomaRefractory marginal zone lymphomaMulticenter cohort studyPrimary refractory diseaseOverall response rateStable diseaseCohort studyComplex cytogeneticsRefractory diseaseFirst-line therapyHigh-risk subsetType of therapyProgression of diseaseInferior OSInferior PFSMedian PFSPartial responsePredictive factorsExperimental therapiesStudy populationEligibility criteriaClinical practicePatientsResponse rateIbrutinib
2021
The rescue therapy in epilepsy project Part 2: Insights from people with epilepsy and families on expert-derived preferred practices
Shafer PO, Santilli N, Buchhalter J, Gilchrist B, Kukla A, French JA, Hirsch LJ. The rescue therapy in epilepsy project Part 2: Insights from people with epilepsy and families on expert-derived preferred practices. Epilepsy & Behavior 2021, 125: 108444. PMID: 34839243, DOI: 10.1016/j.yebeh.2021.108444.Peer-Reviewed Original ResearchCardiac Magnetic Resonance in Cardio-Oncology Advantages, Importance of Expediency, and Considerations to Navigate Pre-Authorization
O’Quinn R, Ferrari VA, Daly R, Hundley G, Baldassarre LA, Han Y, Barac A, Arnold A. Cardiac Magnetic Resonance in Cardio-Oncology Advantages, Importance of Expediency, and Considerations to Navigate Pre-Authorization. JACC CardioOncology 2021, 3: 191-200. PMID: 34396324, PMCID: PMC8352183, DOI: 10.1016/j.jaccao.2021.04.011.Peer-Reviewed Original Research
2019
1240 Increased Mucosal Innate Immune Activation in Hereditary Alpha Trytpasemia Subjects Is Predictive of Clinical Response to Tofacitanib Therapy
Glover S, Davis E, Shirley J, Konnikova L. 1240 Increased Mucosal Innate Immune Activation in Hereditary Alpha Trytpasemia Subjects Is Predictive of Clinical Response to Tofacitanib Therapy. The American Journal Of Gastroenterology 2019, 114: s691-s692. DOI: 10.14309/01.ajg.0000594488.99132.5d.Peer-Reviewed Original ResearchInnate immune activationIntestinal epithelial cellsImmune activationClinical responsePyroptosis levelsAbdominal painGI symptomsClonal mast cell diseaseLevels of pyroptosisSmall bowel biopsyMemory T cellsMcg/LTime of biopsyElevated serum tryptaseMast cell diseaseType of therapyJAK-STAT inhibitorBowel biopsyElevated tryptaseIEC pyroptosisAdalimumab therapyClinical symptomsHistologic evidenceMC activationTryptase levelsImmune checkpoint-based therapy in myeloid malignancies: a promise yet to be fulfilled
Bewersdorf JP, Stahl M, Zeidan AM. Immune checkpoint-based therapy in myeloid malignancies: a promise yet to be fulfilled. Expert Review Of Anticancer Therapy 2019, 19: 393-404. PMID: 30887841, PMCID: PMC6527485, DOI: 10.1080/14737140.2019.1589374.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsImmune checkpoint-based therapyImmune checkpoint inhibitorsAcute myeloid leukemiaMyelodysplastic syndromeNon-small cell lung cancerMultiple immune checkpoint inhibitorsTumor microenvironmentHematopoietic stem cell transplantAdvanced solid malignanciesStem cell transplantCell lung cancerInhibitory immune checkpointsImmunosuppressive tumor microenvironmentType of therapyMinimal residual diseaseInduction chemotherapyMonotherapy useRefractory settingCheckpoint inhibitorsImmune checkpointsTumor cell survivalCell transplantResidual diseaseSafety profileImmune system evasionClinical Overlap Between Myopericarditis and Stress Induced Cardiomyopathy: A Diagnostic and Therapeutic Challenge
Sharma T, Tigadi S, Baldwin J, Tabtabai S. Clinical Overlap Between Myopericarditis and Stress Induced Cardiomyopathy: A Diagnostic and Therapeutic Challenge. American Journal Of Case Reports 2019, 20: 252-257. PMID: 30804319, PMCID: PMC6402271, DOI: 10.12659/ajcr.912169.Peer-Reviewed Original ResearchConceptsErythrocyte sedimentation rateEjection fractionApical ballooningPR depressionHistory of emotional stressElevated erythrocyte sedimentation rateNon-obstructive coronary diseaseNon-obstructive coronary arteriesDiagnosis of myopericarditisPleuritic chest painVentricular apical ballooningReduced ejection fractionT-wave inversionType of therapyFlu-like illnessSecondary to extensionNext 2 daysMasquerading presentationPleuritic painViral prodromeAcute myopericarditisChest painAtypical presentationMyocardial inflammationElectrocardiogram findings
2018
Monitoring Treatment of Wilson Disease
Miloh T, Schilsky M. Monitoring Treatment of Wilson Disease. Clinical Gastroenterology 2018, 143-159. DOI: 10.1007/978-3-319-91527-2_8.Peer-Reviewed Original ResearchWilson's diseaseAdjustment of treatmentType of therapyBetter patient outcomesQuality of lifePhases of treatmentFrequency of monitoringNeurologic findingsMedical therapyKF ringLiver diseaseClinical statusUrine testingPhysical examPatient outcomesDietary restrictionPsychiatric findingsHealth statusCopper intakeTreatment monitoringAppropriate monitoringDiseaseCopper statusTreatmentTherapy
2014
New advances in limb salvage.
Chin JA, Sumpio BE. New advances in limb salvage. Surgical Technology Online 2014, 25: 212-6. PMID: 25433346.Peer-Reviewed Original ResearchCritical limb ischemiaLimb salvageDistal vein patchType of therapyDrug-eluting stentsQuality of lifeEndovascular therapyLimb ischemiaPatient mortalityVein patchPoor outcomeEndovascular interventionTreatment optionsMorbid diseaseVascular surgerySurgical techniqueLimb lossHealthcare costsEpidemiologic problemNew advancesTherapySalvageInterventionFurther research
2010
No Train, No Gain?
Carroll K, Martino S, Rounsaville B. No Train, No Gain? Clinical Psychology Science And Practice 2010, 17: 36-40. DOI: 10.1111/j.1468-2850.2009.01190.x.Peer-Reviewed Original ResearchEvidence-based therapiesEvidence-based treatmentsType of therapyTypes of cliniciansEvidence-based interventionsDelivery of interventionsClinical trialsClinician trainingCliniciansTraining cliniciansPatient problemsComputer-assisted treatmentTherapyOngoing supervisionTreatmentAddiction cliniciansTrialsDidactic trainingRecent seriesInterventionFurther researchImportant new tool
2005
Comparison of hepatitis C treatment patterns in patients with and without psychiatric and/or substance use disorders†
Chainuvati S, Khalid S, Kancir S, Shea M, Edwards J, Sernyak M, Wongcharatrawee S, Garcia‐Tsao G. Comparison of hepatitis C treatment patterns in patients with and without psychiatric and/or substance use disorders†. Journal Of Viral Hepatitis 2005, 13: 235-241. PMID: 16611189, DOI: 10.1111/j.1365-2893.2005.00681.x.Peer-Reviewed Original ResearchConceptsCompletion of therapyVirological responsePatient demographicsSubstance useAntiviral therapyMental illnessHepatitis C virus infectionLiver disease characteristicsC virus infectionNIH Consensus ConferenceType of therapyLiver clinicSVR ratesHCV RNAPositive patientsRelative contraindicationTherapy completionTreatment patternsLiver diseaseTreatment eligibilityDisease characteristicsPatient populationPoor adherenceVirus infectionConsensus conference
2003
Sex Differences in Use of Coronary Revascularization in Elderly Patients After Acute Myocardial Infarction A Tale of Two Therapies
Rathore SS, Foody JM, Radford MJ, Krumholz HM. Sex Differences in Use of Coronary Revascularization in Elderly Patients After Acute Myocardial Infarction A Tale of Two Therapies. CHEST Journal 2003, 124: 2079-2086. PMID: 14665483, DOI: 10.1378/chest.124.6.2079.Peer-Reviewed Original ResearchConceptsAcute myocardial infarctionRisk-standardized ratesPercutaneous coronary interventionCoronary revascularizationElderly patientsCardiac catheterizationRevascularization therapyMedicare patientsCoronary artery bypass graft surgeryArtery bypass graft surgerySex differencesMultivariable logistic regression modelCrude overall ratesBypass graft surgeryCoronary revascularization ratesType of therapyMedical record dataLogistic regression modelsRevascularization useCABG surgeryGraft surgeryMultivariable adjustmentRevascularization ratesCoronary interventionHospital admission
2001
Treatment of Severe Intradialytic Hypotension With the Addition of High Dialysate Calcium Concentration to Midodrine and/or Cool Dialysate
Alappan R, Cruz D, Abu-Alfa A, Mahnensmith R, Perazella M. Treatment of Severe Intradialytic Hypotension With the Addition of High Dialysate Calcium Concentration to Midodrine and/or Cool Dialysate. American Journal Of Kidney Diseases 2001, 37: 294-299. PMID: 11157369, DOI: 10.1053/ajkd.2001.21292.Peer-Reviewed Original ResearchConceptsHigh dialysate calcium concentrationSevere intradialytic hypotensionDialysate calcium concentrationIntradialytic hypotensionBlood pressureEnd-stage renal disease populationCalcium concentrationLow dialysate calciumSeverity of hypotensionMean arterial pressurePeripheral vascular resistanceIntradialytic blood pressureRenal disease populationProspective crossover studyTreatment of patientsMultiple pathogenic factorsType of therapyDialysate calciumHemodynamic instabilityVascular resistanceHemodynamic stabilityArterial pressureCrossover studyCardiac outputCool dialysate
1992
Primary Cutaneous B‐Cell Lymphoma
WATSKY K, LONGLEY B, DVORETZKY I. Primary Cutaneous B‐Cell Lymphoma. Dermatologic Surgery 1992, 18: 951-954. PMID: 1430551, DOI: 10.1111/j.1524-4725.1992.tb02766.x.Peer-Reviewed Original ResearchConceptsPrimary cutaneous B-cell lymphomaCutaneous B-cell lymphomaB-cell lymphomaRadiation therapyNew skin lesionsRemission 12 monthsAdditional radiation therapyType of therapyCombination chemotherapyFavorable prognosisLocal therapyInitial treatmentSystemic diseaseElderly womenLower extremitiesSkin lesionsLast treatmentLocalized lesionsLymphomaTherapyRadiation portPatientsPrognosisLesionsTreatment
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply